Revlimid repurposing -- two organizations, NIA and ADDF, have awarded $4.6 million to a team of researchers to study the effects of the cancer therapy Revlimid for treating patients with Alzheimer's disease in its early stage.
One of these grants is supporting two clinical trials that are planned to go into action. The first step is to recruit 30 eligible male and female adults at a location in Nevada.
Center director said in a PR: "To date, disease-modifying therapies have only used a single drug approach to target Alzheimer's disease pathologies, and they have all failed. These grants will help us explore a novel approach in reducing several pathologies simultaneously."